|
|
|
Net earnings attributable to common stockholders |
$3.20 to $3.45 |
|
Core FFO attributable to common stockholders/unitholders* |
$5.42 to $5.56 |
|
Core FFO attributable to common stockholders/unitholders, excluding Net Promote Income (Expense)* |
$5.50 to $5.64 |
|
Operations – Prologis Share |
|
|
Average occupancy |
96.50% to 97.50% |
|
Cash Same Store NOI* |
8.00% to 9.00% |
|
|
|
Strategic Capital revenue, excluding promote revenue |
$530 to $550 |
|
Net Promote Income (Expense)1 |
$(80) |
|
G&A (in millions) |
|
|
General & administrative expenses |
$420 to $440 |
|
|
|
Development stabilizations |
$3,600 to $4,000 |
|
Development starts |
$3,000 to $3,500 |
|
Acquisitions |
$500 to $1,000 |
|
Contributions |
$1,750 to $2,250 |
|
Dispositions |
$800 to $1,200 |
|
$(950) to $(1,050) |
|
Realized development gains |
$300 to $400 |
Piper Sandler Initiates Coverage On Miromatrix Medical with Overweight Rating, Announces Price Target of $8
Piper Sandler analyst Matt O'Brien initiates coverage on Miromatrix Medical (NASDAQ:MIRO) with a Overweight rating and announces Price Target of $8.